The performance of companies tied to Viagra's legacy presents a complex investment picture . While the initial success generated substantial gains, generic competition have significantly eroded revenue. Investing in related pharmaceutical firms now requires a thorough assessment of patent safeguards, evolving medical changes, and the possibility fo